Millie Wang
AstraZeneca
15 Papers
36 Citations
Millie Wang is an academic researcher from AstraZeneca. The author has contributed to research in topics: Placebo & Tralokinumab. The author has an hindex of 9, co-authored 15 publications. Previous affiliations of Millie Wang include Loughborough University.
Chat about Author
Papers
Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate Results From a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
Michael E. Weinblatt,Mark C. Genovese,Meilien Ho,Sally Hollis,Krystyna Rosiak-Jedrychowicz,Arthur Kavanaugh,David Millson,Gustavo Leon,Millie Wang,Désirée van der Heijde +9 more
TL;DR: This phase III, 52‐week study compared fostamatinib with placebo (for 24 weeks) in patients with active rheumatoid arthritis and an inadequate response to methotrexate (MTX) therapy.
102
Effects of an oral MMP-9 and -12 inhibitor, AZD1236, on biomarkers in moderate/severe COPD: a randomised controlled trial.
Ronald Dahl,Ingrid Louise Titlestad,Ari Lindqvist,Pascal Wielders,Heather Wray,Millie Wang,Viktoria Samuelsson,John Mo,Alison Holt +8 more
TL;DR: No clinical efficacy of AZD1236 was demonstrated in this short-term signal-searching study, although possible evidence of an impact on desmosine may suggest the potential value of selective inhibitors of MMPs in the treatment of COPD in longer term trials.
85
Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma.
William W. Busse,Guy Brusselle,Stephanie Korn,Piotr Kuna,Antoine Magnan,David Cohen,Karin Bowen,Teresa Piechowiak,Millie Wang,Gene L. Colice +9 more
TL;DR: This 40-week, randomised, double-blind trial evaluated the OCS-sparing potential of tralokinumab in patients with severe, uncontrolled asthma requiring maintenance OCS treatment plus inhaled corticosteroids/long-acting β2-agonists.
63
Safety and tolerability of an oral MMP-9 and -12 inhibitor, AZD1236, in patients with moderate-to-severe COPD: a randomised controlled 6-week trial.
Helgo Magnussen,Henrik Watz,Anne Kirsten,Millie Wang,Heather Wray,Viktoria Samuelsson,John Mo,Richard Kay +7 more
TL;DR: Oral AZD1236 at 75 mg twice daily was generally well tolerated and had an acceptable safety profile, and Therapeutic efficacy could not be demonstrated, possibly due to the stable disease and background medications of the patients enrolled in this small, short-term study.
35
Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program.
TL;DR: The ATMOSPHERE clinical development program comprised four randomized, placebo-controlled clinical trials and an open-label study that aimed to assess the efficacy and safety of tralokinumab for the treatment of severe, uncontrolled asthma.
17